Andy Chen
Analyst, Wolf Research
Replay available
Insmed Incorporated (NASDAQ: INSM) Q1 2026 earnings conference call, held 2026-05-07. Replay captured from the company's public earnings webcast.

Analyst, Wolf Research
Analyst, UBS
Analyst, TD Cowen
Analyst, Morgan Stanley
Analyst, ISI
Analyst, Guggenheim
Analyst, Mizuho
Analyst, RBC Capital Markets
Analyst, Lear Inc. Partners
Analyst, Wells Fargo
Analyst, Roth Capital Partners
Chair and Chief Executive Officer
Analyst, Bank of America
Analyst, William Blair
Head of Investor Relations
Analyst, Jefferies
Analyst, Cantor Fitzgerald
Analyst, Truist Securities
Chief Financial Officer
Analyst, Barclays
Analyst, JPMorgan
Thank you for standing by. My name is Danica, and I will be your conference operator today. At this time, I would like to welcome everyone to the InnsMed first quarter 2026 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. Please limit to just one question per caller and then rejoin the queue for any follow-up questions. Thank you. I would now like to turn the call over to Brian Dunn, Head of Investor Relations. Please go ahead. Thank you, Danica. Good day, everyone, and welcome to today's conference call to discuss Invenet's first quarter 2026 financial results and provide an update on our business. Before we begin, please note that today's call will include forward-looking statements. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the projections discussed. Please refer to our filings with the Securities and Exchange Commission for more information. The information we will discuss on today's call is meant for the benefit of the investment community. It is not intended for promotional purposes, and it is not sufficient for prescribing decisions. Today's call will feature prepared comments by Will Lewis, Chair and Chief Executive Officer, and Sarah Blomstein, Chief Financial Officer. After their comments, they will be joined by Martina Flammer, Chief Medical Officer, for the Q&A session. I will now turn the call over to Will. Thank you, Brian. Good m...